[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Inova Medical\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100627217","tarsila-real-world-evidence-study-100627217",false,"NCT07445763","TARSILA Real-World Evidence Study","Real-world Effectiveness of maTernAl RSVpreF vaccInation Against RSV-associated Acute Respiratory ilLness in Infants in BrAzil (TARSILA Study): a Multicentre, Prospective, Test-negative, Case-Control Study","TARSILA","Tarsila Inpatient Study\n\nInclusion Criteria\n\n* Infant born in Brazil.\n* Mother resident in Brazil during the related pregnancy.\n* Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.\n* Infant ≤360 days of age at time of RSV specimen collection.\n* Infant born at ≥37 weeks of gestational age.\n* Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths\u002Fmin for infants \\\u003C2 months or ≥50 breaths\u002Fmin for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).\n\nExclusion Criteria:\n\n* Maternal or infant receipt of any other licensed or investigational RSV preventive product.\n* Infant receipt of blood transfusion or other blood products containing antibodies since birth.\n* Infant previously enrolled in this study.\n* Lack of informed consent from the mother or the infant's legal guardian.\n* Absent or inconclusive RT-qPCR result for RSV.\n* Birth to a mother whose RSVpreF vaccination status could not be confirmed.\n\nTarsila Outpatient Study\n\nInclusion Criteria:\n\n* Infant born in Brazil.\n* Mother resident in Brazil during the related pregnancy.\n* Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.\n* Infant ≤360 days of age at time of RSV specimen collection.\n* Infant born at ≥37 weeks of gestational age.\n* Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths\u002Fmin for infants \\\u003C2 months or ≥50 breaths\u002Fmin for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).\n\nExclusion Criteria:\n\n* Mother or infant receipt of any other licensed or investigational RSV preventive product.\n* Infant receipt of blood transfusion or other blood products containing antibodies since birth.\n* Lack of informed consent from the mother or the infant's legal guardian.\n* Absent or inconclusive RT-qPCR result for RSV.\n* Birth to a mother whose RSVpreF vaccination status could not be confirmed.\n* Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.","ALL","0 Days","360 Days",{"count":21,"type":22},5000,"ESTIMATED","OBSERVATIONAL","The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.",[26,27,28,29,30],"Respiratory Syncytial Virus (RSV)","Maternal Immunization","Acute Respiratory Illness (ARI)","Lower Respiratory Tract Disease","Infant Outcomes",[32,33,34,35,36,37],"respiratory syncytial virus","respiratory syncytial virus bivalent prefusion F vaccine","acute respiratory illness","lower respiratory tract disease","Maternal immunization","Tarsila study","NOT_YET_RECRUITING","2026-02-25",{"date":41,"type":42},"2026-03-03","ACTUAL",{"date":44,"type":22},"2026-04-30",{"date":46,"type":22},"2028-12-31",{"name":48,"class":49},"Inova Medical","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100502433","incidence-associated-factors-and-burden-of-post-covid-19-condition-in-brazil-100502433","NCT05822193","Incidence, Associated Factors, and Burden of Post COVID-19 Condition in Brazil","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Brazilian resident;\n* Symptomatica COVID-19 confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen test for SARS-COV-2 after January 2022, with diagnosis at least 90 days before recruitment.\n\nExclusion Criteria:\n\n* No availability to participate in remote research appointments;\n* Communication difficulty (aphasia, important hearing loss, non-portuguese speaker, severe dementia)\n* Refuse to provide informed consent",true,"18 Years",{"count":59,"type":22},1694,"This is a national retrospective cohort study with internet-based recruitment which intends to enroll 1,694 adult patients with COVID-19 diagnosis during the SARS-CoV-2 omicron wave in Brazil. Participants with confirmed symptomatic COVID-19 after january 2022 will be evaluated in order to assess incidence, potential risk factors and impact of post COVID-19 condition according to the WHO definition on health-related quality of life and other relevant patient-centered outcomes.",[62],"Post-Acute COVID-19 Syndrome","RECRUITING","2025-02-17",{"date":66,"type":42},"2025-02-19",{"date":68,"type":42},"2023-07-21",{"date":70,"type":22},"2025-07-31",{"name":48,"class":49},1,""]